ARCHIVES

ODAC Votes to Nix Amgen’s Drug Xgeva For Proposed Prostate Cancer Indication

This article is from The Cancer Letter archive.

Vol. 38 No. 07 | February 17, 2012

Download PDF Visit The Full Archive

Related Articles

NCI T BE More Flexible In Funding RFAs Above Paylines

June 23, 1989

Interview: Joseph Jacobs Claims “Political Extortion” By The “Harkinites”

October 14, 1994

ODAC Okays Photofrin for Obstructive Esophageal Cancer

September 23, 1994

Perifosine Fails Primary Endpoint, Zentaris CEO Explores Options

April 27, 2012

NCI Diet Guideline Outlined At Senate Hearing

November 22, 1985

UT Health System’s Probe Finds Lapses at MD Anderson, CPRIT—But No Nepotism

June 15, 2012